T1	intervention 25 45	Biosimilar LA-EP2006
T2	control 50 73	Reference Pegfilgrastim
T3	condition 96 107	Neutropenia
T4	eligibility 111 214	Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy
T5	No-of-participants 902 905	308
T6	eligibility 791 889	early-stage breast cancer patients receiving adjuvant or neoadjuvant myelosuppressive chemotherapy
T7	outcome-Measure 1269 1320	duration of severe neutropenia (DSN) during cycle 1
T8	outcome 1542 1545	DSN
T9	intervention-participants 1617 1620	155
T10	control-participants 1654 1657	153
T11	outcome 1932 1947	Safety profiles
T12	outcome 1982 2007	No neutralizing antibodie
T13	outcome 1678 1698	treatment difference
T14	outcome 1840 1869	Secondary efficacy parameters
T15	outcome 2177 2196	efficacy and safety
